Jim Mullen is a recognized biotech leader with more than 40 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. He recently served at Editas Medicine, a clinical-stage biotechnology company, Board of Directors as Chairman from March 2018 until February 2021 when was appointed as President and CEO. In June 2022, Jim became Editas Executive Chairman until May 2023. Previously, he served as Chief Executive Officer of Patheon NV, a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. (Thermo Fisher), in August 2017. Before joining Patheon, Jim served as Chief Executive Officer and President at Biogen, Inc. (Biogen), one of the world’s largest biotechnology companies. Prior to being named Chief Executive Officer, he held various operating positions at Biogen, including Chief Operating Officer, Vice President, International, and Vice President, Operations.

Jim also serves on the Board of Directors of Thermo Fisher Scientific. He previously served on the Board of Directors of Patheon, Biogen, Insulet and PerkinElmer, Inc. He was also Chairman of the Board of Directors of the Biotechnology Innovation Organization. 

Jim holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.